JGC
PTHS

J. Goldman & Co’s Pelthos Therapeutics PTHS Stock Holding History

J. Goldman & Co’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
38,075
-12,340
-24% -$317K 0.03% 441
2026
Q1 		$1.06M Sell
50,415
-27,591
-35% -$654K 0.03% 408
2025
Q4 		$2.42M Buy
+78,006
New +$2.25M 0.06% 293

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

J. Goldman & Co's PTHS Position: Q2 2026 in Review

J. Goldman & Co reduced its Pelthos Therapeutics (PTHS) stake by 24% in Q2 2026, selling an estimated $317K and leaving 38,075 shares worth $1.08M. The position accounts for 0.03% of the portfolio, ranked #441.

J. Goldman & Co first reported a position in PTHS in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.42M in Q4 2025. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • J. Goldman & Co held 38,075 shares of Pelthos Therapeutics worth $1.08M as of Q2 2026.
  • J. Goldman & Co sold 12,340 Pelthos Therapeutics shares in Q2 2026, an estimated $317K.
  • Pelthos Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q2 2026, its #441 holding.
  • J. Goldman & Co first reported a position in Pelthos Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's Pelthos Therapeutics position peaked at $2.42M in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.